During the 18 months of administration and monitoring, significantly fewer incidents of worsening heart failure or even death were recorded in the three groups of diabetes, prediabetes, and non-diabetes patients treated with the SGLT2 inhibitor dapagliflozin compared to matching groups of patients receiving a placebo [9,10,11]. The gene discussed is SLC5A2; the disease is heart failure.